Conclusion: without the return of the product, no definitive conclusion can be made regarding the clinical observation.No unique device identifier (serial/lot) numbers were provided; without this information it cannot be determined whether this event has been previously reported.(b)(4).Citation: title: the clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the us melody valve in vestigational device exemption trial.Authors: john p.Cheatham, md; william e.Hellenbrand, md; evan m.Zahn, md; thomas k.Jones, md; darren p.Berman, md; julie a.Vincent, md; doff b.Mcelhinney, md journal: circulation.2015;131:1960-1970.
|
Medtronic received information via literature review that a study was performed to evaluate the clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the us melody valve investigational device exemption trial.The study population included 171 patients (mean age of 19 years), 150 of which were implanted with medtronic melody transcatheter pulmonary valve (tpv) (serial numbers not provided).Among all patients, 4 deaths occurred, which included: 1 of multisystem failure resulting from sepsis/endocarditis and 3 of other causes with no apparent relationship to the melody valve (1 of respiratory failure and 2 of unknown causes).Among all patients, 32 adverse events occurred, which included: 32 patients underwent right ventricular outflow tract reintervention for obstruction (n=27, with stent fracture in 22), endocarditis (n=3, 2 with stenosis and 1 with pulmonary regurgitation), or right ventricular dysfunction (n=2).Eleven patients had the tpv explanted as an initial or second reintervention, pulmonary hypertension and increasing rv pressures was also noted in one patient.Five-year freedom from reintervention and explantation was 76±4% and 92±3%, respectively.A conduit pre-stent and lower discharge right ventricular outflow tract gradient were associated with longer freedom from reintervention.In the 113 patients who were alive and reintervention free, the follow-up gradient (median, 4.5 years after implantation) was unchanged from early post-tpv replacement, and all but 1 patient had mild or less pulmonary regurgitation.Almost all patients were in new york heart association class i or ii.More severely impaired baseline spirometry was associated with a lower likelihood of improvement in exercise function after tpv replacement.Conclusions¿tpv replacement with the melody valve provided good hemodynamic and clinical outcomes up to 7 years after implantation.Primary valve failure was rare.The main cause of tpv dysfunction was stenosis related to stent fracture, which was uncommon once prestenting became more widely adopted.
|